Extracellular vesicles from ovarian cancer tumor spheroids harbor disease-related and survival-associated proteins

Abstract

Aim: Extracellular vesicles (EVs) play a pivotal role in tumor progression, influencing the tumor microenvironment. Despite significant research, the targeted analysis of EVs directly derived from primary tumors remains limited, particularly in ovarian cancer. The majority of existing studies have focused on EVs derived from peritoneal fluid (ascites), which encompasses contributions from different cell types. This study aims to isolate and characterize EVs secreted specifically by ovarian cancer spheroids derived from primary patient ascites.

Methods: A three-dimensional cell culture model was employed to cultivate tumor spheroids in a defined medium, with EVs purified via differential ultracentrifugation and size-exclusion chromatography. Purified EVs were characterized by nanoparticle tracking analysis, nanoflow cytometry, and electron microscopy prior to performing high-resolution mass spectrometry.

Results: This approach allowed the identification of known cancer-associated proteins, including danger molecules, which are linked to poor prognosis. Moreover, enzyme-linked immunosorbent assay (ELISA) analysis demonstrated that the ascites abundance levels of novel candidates [RAB14 (Ras-related protein Rab-14), SCAMP3 (secretory carrier membrane protein 3), and FAM3C (FAM3 metabolism regulating signaling molecule C)] correlated with patients’ progression-free survival, further validating their clinical relevance. Finally, we used the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database to compare our dataset with The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data. Thereby, we revealed a signature of three TOP genes encoding proteins within our dataset (CORO1B, LAMP2, MSLN), which were differentially expressed in ovarian cancer patients compared to healthy individuals.

Conclusion: This study provides the first proteomic profile of EVs derived directly from primary tumor spheroids, and paves the way for a better mechanistic understanding of EV-associated proteins and for the development of biomarkers or therapeutic strategies.

Keywords

Extracellular vesicles / ovarian cancer / HGSOC / primary 3D spheroids / tumor microenvironment

References

[1] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[2] Fantone S,Tossetta G.NRF2/KEAP1 signaling inhibitors in gynecologic cancers.Expert Rev Anticancer Ther2024;24:1191-4

[3] Tan DSP,Kaye SB.Mechanisms of transcoelomic metastasis in ovarian cancer.Lancet Oncol2006;7:925-34

[4] Kipps E,Kaye SB.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Nat Rev Cancer2013;13:273-82 PMCID:PMC4673904

[5] Worzfeld T,Huber M.The unique molecular and cellular microenvironment of ovarian cancer.Front Oncol2017;7:24 PMCID:PMC5319992

[6] Kalluri R.The role of extracellular vesicles in cancer.Cell2023;186:1610-26 PMCID:PMC10484374

[7] Rodrigues G,Kenific CM.Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis.Nat Cell Biol2019;21:1403-12 PMCID:PMC7354005

[8] Shield K,Ahmed N.Multicellular spheroids in ovarian cancer metastases: biology and pathology.Gynecol Oncol2009;113:143-8

[9] Reinartz S,Adhikary T.A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome.Genome Biol2016;17:108 PMCID:PMC4877997

[10] Iring A,Albarrán-Juárez J.Shear stress-induced endothelial adrenomedullin signaling regulates vascular tone and blood pressure.J Clin Invest2019;129:2775-91 PMCID:PMC6597232

[11] Kiweler M,Graumann J.MARMoSET - extracting publication-ready mass spectrometry metadata from RAW files.Mol Cell Proteomics2019;18:1700-2 PMCID:PMC6683000

[12] Cox J.MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.Nat Biotechnol2008;26:1367-72

[13] Bhagwat A,Hayat S.Autonomics: unified statistical modeling of omics data. 2025.

[14] Ritchie ME,Wu D.limma powers differential expression analyses for RNA-sequencing and microarray studies.Nucleic Acids Res2015;43:e47 PMCID:PMC4402510

[15] Bortot B,Rampazzo E.Small extracellular vesicles from malignant ascites of patients with advanced ovarian cancer provide insights into the dynamics of the extracellular matrix.Mol Oncol2021;15:3596-614 PMCID:PMC8637559

[16] Cooper TT,Liu J.Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer.J Ovarian Res2024;17:149 PMCID:PMC11253408

[17] Dorayappan KDP,Park D.ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis.J Extracell Biol2024;3:e92 PMCID:PMC11080709

[18] Gu R,Dai S.Identification of exosome-related SERPINB1 as a novel predictor for tumor immune microenvironment and clinical outcomes in ovarian cancer.J Ovarian Res2025;18:65 PMCID:PMC11954311

[19] Ferreira GA,Izumi C.Proteomic analysis of exosomes secreted during the epithelial-mesenchymal transition and potential biomarkers of mesenchymal high-grade serous ovarian carcinoma.J Ovarian Res2023;16:232 PMCID:PMC10685605

[20] Jo A,Medina JE.Inaugurating high-throughput profiling of extracellular vesicles for earlier ovarian cancer detection.Adv Sci2023;10:e2301930 PMCID:PMC10520636

[21] Kong L,Yao Y.Ascites-derived CDCP1+ extracellular vesicles subcluster as a novel biomarker and therapeutic target for ovarian cancer.Front Oncol2023;13:1142755 PMCID:PMC10352483

[22] Vyhlídalová Kotrbová A,Mikulová A.Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.J Extracell Vesicles2024;13:e12420 PMCID:PMC10942866

[23] Quiralte M,Yagüe-Fernández M.Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer.J Clin Invest2024;134:e176161 PMCID:PMC11093605

[24] Runz S,Rupp C.Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM.Gynecol Oncol2007;107:563-71

[25] Trinidad CV,Cheng S.Lineage specific extracellular vesicle-associated protein biomarkers for the early detection of high grade serous ovarian cancer.Sci Rep2023;13:18341 PMCID:PMC10603107

[26] Wu J,Zhi S.Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response.J Transl Med2021;19:381 PMCID:PMC8424990

[27] Yokoi A,Yasui T.Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires.Sci Adv2023;9:eade6958 PMCID:PMC10328412

[28] Chen R,Chen J,Kang R.Pattern recognition receptors: function, regulation and therapeutic potential.Signal Transduct Target Ther2025;10:216 PMCID:PMC12246121

[29] Singh B,Muthukrishnan U.Extracellular histones as exosome membrane proteins regulated by cell stress.J Extracell Vesicles2025;14:e70042 PMCID:PMC11840699

[30] Palanissami G.RAGE and its ligands: molecular interplay between glycation, inflammation, and hallmarks of cancer-a review.Horm Cancer2018;9:295-325 PMCID:PMC10355895

[31] Yin F,Qiao Y.Tumor-derived vesicles in immune modulation: focus on signaling pathways.Front Immunol2025;16:1581964 PMCID:PMC12119490

[32] Zhong Y,Wang C.Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer.J Immunother Cancer2025;13:e011230 PMCID:PMC11873354